Zota Health Care LImited stock analysis

Let me take you through the key financial and operational highlights for Q4 and full year of FY26. We are pleased to report a strong financial performance for the year, reflecting the scale-up of our Davaindia retail business and improving operational leverage. Consol revenue from operations for FY26 stood at INR 53,865 lakhs, registering a robust Y-o- Y growth of 83.86%, driven primarily by continuous expansion of D

Himanshu Zota: Yes, these margins are sustainable, and in fact, we continue to see improvement. The overall margin expansion is driven by both COCO and FOFO formats, as both are benefiting from scale and the private label model. You had mentioned earlier that around 400–600 stores were under process.

Further to dig it down, store age 24 plus months have recorded SSG of 35% to 40%, while store age between 12 to 24 months have achieved even stronger SSG of 55% to 60% in this financial year. We increased our stake in Everyday Herbal Beauty Care Limited to 87.78%, reinforcing our backward integration strategy and enhancing control over our consumer product portfolio. We have strengthened our brand visibility and cons

Himanshu Zota: This mainly pertains to pre-operative expenses related to stores under development. Specifically, these include items such as drug licenses and other regulatory approvals that are in process before a store becomes operational. These costs are incurred during the store setup phase (prior to opening) and are therefore classified under intangible assets under development.